新辅助化疗对非小细胞肺癌行完全性切除术患者生存期的影响  

Impact of Neoadjuvant Chemotherapy on Lifetime of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Complete Resection

作　　者：王胜[1] 开金丹 徐元涛[1] 熊飞[1] 

机构地区：[1]湖北省肿瘤医院胸外科,湖北武汉430079

出　　处：《武汉大学学报（医学版）》2016年第5期797-800,共4页Medical Journal of Wuhan University

摘　　要：目的:观察新辅助化疗对非小细胞肺癌行完全性切除术患者生存期的影响。方法:临床纳入100例可切除的非小细胞肺癌患者,根据治疗方案的不同分为研究组与对照组。对照组进行直接手术治疗,研究组在对照组基础上进行新辅助化疗(顺铂+长春瑞滨)。观察两组患者中期生存率、中位生存时间以及术后并发症发生率等。结果:在生存率方面,研究组1年、3年、5年生存率分别为80%,52%,22%,均高于对照组(72%,36%,14%);研究组中位生存时间33.02个月,对照组中位生存时间28.05个月,组间差异有统计学意义(P<0.05)。术后并发症方面,研究组术后并发症发生率为16%,对照组术后并发症发生率为18%,组间差异无显著性(P>0.05)。结论:新辅助化疗在临床治疗非小细胞肺癌行完全性切除术患者中,有较高的临床价值,其与手术相互配合,能够在不增加手术风险的基础上提升患者的总生存率,对肺癌患者的临床综合治疗以及预后均有着重要意义。Objective：To observe the impact of neoadjuvant chemotherapy on lifetime of patient with NSCLC treated with complete resection.Methods：One hundred patients with NSCLC treated with complete resection were clinically chosen and divided into study group and control group according to different treatment methods.Control group were given direct surgical treatment while study group were given neoadjuvant chemotherapy（cis-platinum ＋ vinorelbine）on basis of surgery.Medium-term survival rate,median survival time and occurrence rate of postoperative complications of the two groups were observed.Results：On the survival rate,survival rate of 1year,3years and 5years of study group were separately 80.0%,52.0% and 22.0%,which all were higher than that of control group as 72.0%,36.0% and 14.0%;Median survival time of study group was 33.02 months versus 28.05 months in control group（P〈0.05）.Occurrence rate of postoperative complications of study group was 16% while that of control group was 18%（P〉0.05）.Conclusion：Neoadjuvant chemotherapy has high clinical value in treating patients with NSCLC treated with complete resection.And combined with surgical method,it can improve thesurvival rate of patients without increasing risks of surgery,so it has great significance on both clinical comprehensive treatment and prognosis of patients with lung cancer.

关 键 词：顺铂 长春瑞滨 新辅助化疗 非小细胞肺癌 疗效 

分 类 号：R734.2[医药卫生—肿瘤]